通心络改善冠心病患者内皮细胞功能的相关研究
|
摘要
目的探讨通心络对冠心病患者内皮细胞功能的改善情况。方法将45例患者随机分成两组。一组给予常规的冠心病药物治疗,共22例。一组在常规药物治疗的基础上加服通心络胶囊,共23例。检测患者服药前及服药后一段时间NO、SOD、MDA的指标。结果治疗前,各组患者血清SOD、MDA、NO水平差异无统计学意义(P>0.05)。10天左右,加服通心络的冠心病患者血清中MDA水平降低,SOD、NO水平升高。结论通心络胶囊具有改善内皮细胞功能障碍、清除自由基、抑制脂质过氧化的作用,能够有效防治心肌无再流,缩小心肌梗死面积。
Objective To explore the improvement of endothelial function of tongxinluo in patients with coronary heart disease. Methods 45 patients were randomly divided into two groups. A group of 22 patients were given a routine drug treatment for coronary heart disease. A group of 23 cases were treated with Tongxinluo Capsule on the basis of conventional drug treatment. The indexes of NO, SOD and MDA were measured before and after taking medicine. Results The serum SOD, MDA and NO level of serum were not significantly different in the patients before treatment(P > 0.05). In the 10 days or so, the levels of MDA in patients with coronary heart disease were reduced, and SOD and NO increased. Conclusion Tongxinluo capsule has the function of improving endothelial dysfunction, scavenging free radicals and inhibiting lipid peroxidation, which can effectively prevent myocardial infarction and reduce the area of myocardial infarction.
Objective To explore the improvement of endothelial function of tongxinluo in patients with coronary heart disease. Methods 45 patients were randomly divided into two groups. A group of 22 patients were given a routine drug treatment for coronary heart disease. A group of 23 cases were treated with Tongxinluo Capsule on the basis of conventional drug treatment. The indexes of NO, SOD and MDA were measured before and after taking medicine. Results The serum SOD, MDA and NO level of serum were not significantly different in the patients before treatment(P > 0.05). In the 10 days or so, the levels of MDA in patients with coronary heart disease were reduced, and SOD and NO increased. Conclusion Tongxinluo capsule has the function of improving endothelial dysfunction, scavenging free radicals and inhibiting lipid peroxidation, which can effectively prevent myocardial infarction and reduce the area of myocardial infarction.
引文
[1]国际心脏病学会和协会及世界卫生组织临床命名标准化专题组.缺血性心脏病的命名及诊断标准[S].中华心血管病杂志,1981,9(1):75.
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].1版.北京:中国医药科技出版社,2002:68-73.
[3]陈伟伟,高润霖,刘力生,等.中国心血管病报告2016概要[J].中国循环杂志,2017,32(6):521-531.
[4]杨跃进,赵京林,孟亮,等.中药通心络(超微粉碎)对猪急性心肌梗死再灌注后无再流的影响[J].中国中西医结合杂志,2006,26(1):49-53.
[5]苗旺,刘恒方,杨期东,等.通心络对颈动脉粥样硬化斑块患者内皮祖细胞增殖能力的影响[J].中国实用神经疾病杂志,2010,13(15):44-45.
[6]Waschke J,Curry FE,Adamson RH,et al.Regulation of act in dynamics is critical for endothelial barrier functions[J].Am J Physiol Hear t Circ Physio l,2005,288(3):H1296-1305.
[7]许晶.通心络胶囊治疗冠心病心绞痛的疗效观察[J].中国卫生标准管理,2017,8(1):89.
[8]高怀林,王玲玲,贾振华,等.通心络超微粉对大鼠损伤的内皮细胞骨架蛋白的影响[J].中医杂志,2010,51(10):931-933.
[9]唐元升,李吉发,朱兴雷,等.实验家兔血管球囊损伤后血管平滑肌细胞增殖和迁移及通心络对其影响[J].疑难病杂志,2004,3(2):69-72.
[10]马琦琳,张赛丹,宁阳根,等.通心络对急性冠脉综合征介入治疗术患者内皮功能和高敏C反应蛋白的影响[J].中南大学学报(医学版),2009,34(6):550-554.
[11]王文玉,刘英斌,孙勇.通心络胶囊对急性冠脉综合症患者介入治疗后炎症因子的影响[J].心脑血管病防治,2009,9(4):308-309.
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].1版.北京:中国医药科技出版社,2002:68-73.
[3]陈伟伟,高润霖,刘力生,等.中国心血管病报告2016概要[J].中国循环杂志,2017,32(6):521-531.
[4]杨跃进,赵京林,孟亮,等.中药通心络(超微粉碎)对猪急性心肌梗死再灌注后无再流的影响[J].中国中西医结合杂志,2006,26(1):49-53.
[5]苗旺,刘恒方,杨期东,等.通心络对颈动脉粥样硬化斑块患者内皮祖细胞增殖能力的影响[J].中国实用神经疾病杂志,2010,13(15):44-45.
[6]Waschke J,Curry FE,Adamson RH,et al.Regulation of act in dynamics is critical for endothelial barrier functions[J].Am J Physiol Hear t Circ Physio l,2005,288(3):H1296-1305.
[7]许晶.通心络胶囊治疗冠心病心绞痛的疗效观察[J].中国卫生标准管理,2017,8(1):89.
[8]高怀林,王玲玲,贾振华,等.通心络超微粉对大鼠损伤的内皮细胞骨架蛋白的影响[J].中医杂志,2010,51(10):931-933.
[9]唐元升,李吉发,朱兴雷,等.实验家兔血管球囊损伤后血管平滑肌细胞增殖和迁移及通心络对其影响[J].疑难病杂志,2004,3(2):69-72.
[10]马琦琳,张赛丹,宁阳根,等.通心络对急性冠脉综合征介入治疗术患者内皮功能和高敏C反应蛋白的影响[J].中南大学学报(医学版),2009,34(6):550-554.
[11]王文玉,刘英斌,孙勇.通心络胶囊对急性冠脉综合症患者介入治疗后炎症因子的影响[J].心脑血管病防治,2009,9(4):308-309.